Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics is a life sciences instrumentation company that provides an end-to-end solution for genome analysis with its scalable OGM platform, high-throughput Stratys system, and VIA platform for data integration. The company's strong sales growth potential and impressive technological advancements, such as the OMKar computational tool for constructing digital karyotypes and isotachophoresis for high-purity DNA and RNA isolation, make it a promising stock despite risks of lower market uptake or utilization and the need for additional capital in the next 12 months.

Bears say

Bionano Genomics is facing financial struggles with a negative cash flow from operations and a high level of debt, which may lead to the need for additional capital in the near future. Although the company reported a top- and bottom-line beat for 4Q25, they still experienced a YoY decline in revenue and have provided a lower revenue guidance for FY2026. Additionally, while OGM technology has potential for growth, the current published clinical evidence is limited and the company is heavily dependent on the success and adoption of this technology, which carries inherent risks.

Bionano Genomics (BNGO) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Bionano Genomics (BNGO) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.